


Category Award Digital Health

"Acer Medical" VeriSee GLC



Acer Incorporated

宏碁股份有限公司



Winning Reason

Glaucoma is the second leading cause of vision loss worldwide and is characterized by its irreversible nature. Our AI-assisted glaucoma screening software leverages a decade of clinical data from National Taiwan University Hospital, validated by a consensus of three expert ophthalmologists. By utilizing AI to analyze critical pathological markers in color fundus images, the system achieves a diagnostic accuracy of 85%, significantly accelerating the diagnostic process and enabling large-scale population screening. The solution has secured medical device certifications in Taiwan (TFDA), Thailand, Malaysia, and Indonesia, demonstrating robust export potential for global healthcare markets.

Product Feature

VeriSee GLC is a state-of-the-art AI software that assists clinicians in identifying glaucoma suspects using standard color fundus images. Key Features: 1. Triple-Indicator Evaluation: Analyzes vertical cup-to-disc ratio (VCDR), superior/inferior rim-to-disc ratio (RDR), and retinal nerve fiber layer (RNFL) defects to ensure alignment with ophthalmological standards. 2. Proven Performance: Validated by clinical trials with 90.3% sensitivity, 82.1% specificity, and 85.0% accuracy. 3. AI Explainability: Outlines optic cup/disc contours and provides numerical values, offering transparent evidence for clinical decisions. 4. Efficient Workflow: Integrates with fundus cameras for rapid analysis and timely referrals in checkup centers and clinics.

<https://bcaward.computex.biz/>